Repurposing With Purpose: Treatment of Bachmann-Bupp Syndrome With Eflornithine and Implications for Other Polyaminopathies.
Level 4 - case-series / case-control
Uncontrolled case series describing treatment of an index case and five additional patients.
PubMed 40167220 · doi:10.1002/ajmg.c.32138
What was done
This paper describes a drug repurposing framework for Bachmann-Bupp Syndrome (BABS), a rare neurodevelopmental disorder caused by gain-of-function variants in the ODC1 gene and characterized by developmental delay, hypotonia, and alopecia. The report details the identification and clinical treatment of an index patient using repurposed eflornithine (alpha-difluoromethylornithine, DFMO), followed by treatment in a small cohort.
What was found
The abstract reports no quantitative clinical efficacy, biomarker, or safety metrics. It reports that the first identified patient received DFMO within 16 months, and five additional patients with BABS are currently being treated with DFMO.
Why it matters
It demonstrates a rapid translation and drug repurposing model for an ultra-rare genetic disorder that may inform therapeutic strategies for other polyaminopathies.
Limits
No quantitative efficacy or safety data are presented in the abstract. The evidence is derived from an uncontrolled case series with an extremely small sample size (n = 6).